Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

Origenis GmbH (DE)

Origenis GmbH is a privately held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis, and characterization to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis' approach has been validated by multiple partners resulting in a significant IP and R&D portfolio that ensures strong patent protection. *

 

Period Start 2005-11-01 splitoff (MBO)
  Group Origenis (Group)
  Predecessor Morphochem (Group)
Product Industry drug discovery services
Persons Person Almstetter, Michael (Origenis 202012 Managing Director)
  Person 2 Thormann, Michael (Origenis 200609 Managing Director)
     
Region Region Martinsried
  Country Germany
  Street 19a Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-7801676-0
    Address record changed: 2022-09-18
     
Basic data Employees B: 11 to 50 (2014-11-01)
     
    * Document for »About Section«: Neuron23 Inc.. (12/16/20). "Press Release: Neuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group". South San Francisco, CA.
     
   
Record changed: 2024-12-29

Advertisement

Picture Swiss Biotech Association LSG Swiss Biotech Days 2025 Basel 650x200px

More documents for Origenis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x300px




» top